Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Liminal BioSciences Inc. LMNL

Liminal BioSciences is a biopharmaceutical company focused on the discovery and development of novel, small molecule drug candidates for the treatment of patients suffering from fibrotic or inflammatory diseases that have a high unmet medical need. Liminal BioSciences operates on an integrated basis from our talent hubs in Laval, Quebec, Canada, and Cambridge, UK. Our common shares are listed for trading on the Nasdaq Global Market.


NDAQ:LMNL - Post by User

Bullboard Posts
Comment by stockman6767on Dec 18, 2017 11:48am
163 Views
Post# 27178926

RE:Look at the fibrosis lung clearing with Ryplazim (page 8)

RE:Look at the fibrosis lung clearing with Ryplazim (page 8)BioFinder, the slide you point to (slide 8) is interesting. While they are refering the lung xrays for PG deficiency, the condition may be somewhat similar to IPF in the lung and hopefully treated by PG as well. This may well be how PLI tumbled to the idea trying PG to treat IPF - the similarity between the PG deficient lung xray that they already have in trial and xrays of lungs suffering from IPF. This of course is purely my speculation.
Bullboard Posts